Analyst Tim Anderson of Bank of America Securities reiterated a Buy rating on Merck & Company, reducing the price target to $98.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Buy rating due to a combination of factors including Merck & Company’s current undervaluation and its potential for growth. Despite some near-term challenges, such as the decline in Gardasil sales and the anticipated competition for Keytruda, Anderson believes the stock is priced too low relative to its growth prospects.
Anderson maintains a price objective of $98, suggesting a significant upside from the current price of $87.50. He highlights the company’s promising pipeline, including upcoming launches and catalysts like Winrevair, which could drive future growth. Additionally, the use of a slightly higher price-to-earnings multiple reflects confidence in Merck’s ability to deliver on its long-term potential.
In another report released on October 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $102.00 price target.